Oran Baris purchased $284K of AMRZ

Oran Baris (Chief Financial Officer) purchased 6,000 shares of Amrize Ltd (AMRZ) at an average of $47.26 ($47.13–$47.38, $0.28M total) across 2 trades over 2026-08-11 to 2026-08-12.

Original reporting
SEC EDGAR · Oran Baris
Published Aug 13, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMRZ
Bullish
low confidence
Mentioned
$AMRZ
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishLow
01

Why it matters

The newest fact is the CFO’s open-market purchase amount, price range, and timing, which may slightly influence sentiment but does not change fundamentals in the filing.

02

Market read

Traders may note the insider buying as a small positive sentiment datapoint, but there is no new guidance, contract, or earnings information.

03

What to watch

The article does not disclose whether the purchase was part of any broader compensation or tax-related activity, and it provides no performance or guidance context.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-13, covering purchases on 2026-08-11 to 2026-08-12

Background

This is an SEC Form 4 insider transaction disclosure for Amrize Ltd (AMRZ).

Company-level read

Ticker impact

$AMRZBullishLow confidence
Context

CFO Oran Baris filed a Form 4 open-market purchase of 6,000 AMRZ shares at about $47.13 to $47.38 per share.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine insider open-market purchase with no 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by liquidity needs, diversification, or pre-existing personal plans, so the signal may be weak.

Key entities

  • Amrize Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Oran Baris

    Chief Financial Officer who purchased AMRZ shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMRZHigh

Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.